ICER Asking for Public Comment on Benefits of CF Therapies with Focus on Vertex
The Institute for Clinical and Economic Review (ICER) is planning to evaluate and compare the clinical effectiveness and value of cystic fibrosis treatments now available or awaiting approval, with a tentative focus on several by Vertex Pharmaceuticals. According to information provided in an ICER press release, the institute intends…